AIM2-driven inflammasome activation in heart failure
2021; Oxford University Press; Linguagem: Inglês
10.1093/cvr/cvab202
ISSN1755-3245
AutoresZsófia Onódi, Mihály Ruppert, Dániel Kucsera, Alex Ali Sayour, Viktória É. Tóth, Gábor Koncsos, Julianna Novák, Gábor B. Brenner, András Makkos, Tamás Baranyai, Zoltán Giricz, Anikó Görbe, Przemysław Leszek, Mariann Gyöngyösi, Iván Horváth, Rainer Schulz, Béla Merkely, Péter Ferdinandy, Tamás Radovits, Zoltán V. Varga,
Tópico(s)Kawasaki Disease and Coronary Complications
ResumoInterleukin-1β (IL-1β) is an important pathogenic factor in cardiovascular diseases including chronic heart failure (HF). The CANTOS trial highlighted that inflammasomes as primary sources of IL-1 β are promising new therapeutic targets in cardiovascular diseases. Therefore, we aimed to assess inflammasome activation in failing hearts to identify activation patterns of inflammasome subtypes as sources of IL-1β.
Referência(s)